The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

Simple item page
dc.contributor.authorGraff, R.
dc.contributor.authorPettersson, A.
dc.contributor.authorLis, R.
dc.contributor.authorDupre, N.
dc.contributor.authorJordahl, K.
dc.contributor.authorNuttall, E.
dc.contributor.authorRider, J.
dc.contributor.authorFiorentino, M.
dc.contributor.authorSesso, H.
dc.contributor.authorKenfield, S.
dc.contributor.authorLoda, M.
dc.contributor.authorGiovannucci, E.
dc.contributor.authorRosner, B.
dc.contributor.authorNguyen, P.
dc.contributor.authorSweeney, C.
dc.contributor.authorMucci, L.
dc.date.issued2015
dc.description.abstractBackground. In the United States, half of men with prostate cancer harbor the androgenregulated gene fusion TMPRSS2:ERG. We hypothesized that men with TMPRSS2:ERG positive tumors are more responsive to androgen deprivation therapy (ADT). Methods. We studied a cohort of 239 men with prostate cancer from the Physicians’ Health Study and Health Professionals Follow-up Study who received ADT during their disease course. Fusion status was assessed on available tumor tissue by immunohistochemistry for ERG protein expression. We used Cox models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for assessment of prostate cancer-specific mortality after ADT initiation.
dc.description.statementofresponsibilityRebecca E. Graff, Andreas Pettersson, Rosina T. Lis, Natalie DuPre, Kristina M. Jordahl, Elizabeth Nuttall, Jennifer R. Rider, Michelangelo Fiorentino, Howard D. Sesso, Stacey A. Kenfield, Massimo Loda, Edward L. Giovannucci, Bernard Rosner, Paul L. Nguyen, Christopher J. Sweeney, Lorelei A. Mucci and (on behalf of the Transdisciplinary Prostate Cancer Partnership)
dc.identifier.citationProstate, 2015; 75(9):897-906
dc.identifier.doi10.1002/pros.22973
dc.identifier.issn0270-4137
dc.identifier.issn1097-0045
dc.identifier.orcidSweeney, C. [0000-0002-0398-6018]
dc.identifier.urihttp://hdl.handle.net/2440/103786
dc.language.isoen
dc.publisherWiley
dc.rights© 2015 Wiley Periodicals, Inc.
dc.source.urihttps://doi.org/10.1002/pros.22973
dc.subjectTransdisciplinary Prostate Cancer Partnership ToPCaP
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectNeoplasms, Hormone-Dependent
dc.subjectOncogene Proteins, Fusion
dc.subjectImmunohistochemistry
dc.subjectProportional Hazards Models
dc.subjectSurvival Analysis
dc.subjectCohort Studies
dc.subjectFollow-Up Studies
dc.subjectProspective Studies
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectNonsteroidal Anti-Androgens
dc.subjectSurveys and Questionnaires
dc.titleThe TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications